ABBV vs DBD · P/E 81, rev $61.16B vs P/E 28, rev $3.75B
AbbVie Inc (ABBV) versus Diebold Nixdorf, Incorporated (DBD) — a side-by-side from cached financials, not a winner call.
AbbVie Inc (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
Diebold Nixdorf, Incorporated (DBD) is a software - application company listed on US.
Latest reported ABBV revenue for 2025-12-31 was $61.16B. Net income was $4.23B. Revenue was up 305.0% from 2024-12-31 to 2025-12-31. ABBV currently screens at market cap $334.34B and trailing P/E 80.5.
Latest reported DBD revenue for 2024-12-31 was $3.75B. Net income was -$14.5M. Revenue was up 130.3% from 2023-12-31 to 2024-12-31. DBD currently screens at market cap $2.82B and trailing P/E 28.1.
ABBV currently screens at market cap $334.34B and trailing P/E 80.5. DBD currently screens at market cap $2.82B and trailing P/E 28.1.
Not investment advice. Open the ABBV and DBD stock pages for the full models.
Not investment advice.